Financial Gravity Asset Management’s Corcept Therapeutics CORT Stock Holding History

Financial Gravity Asset Management’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	$2K	Buy	+86	New	+$1.81K	﹤0.01%	306

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Financial Gravity Asset Management's CORT Position: Q4 2020 in Review

Financial Gravity Asset Management opened a new position in Corcept Therapeutics (CORT) in Q4 2020: 86 shares worth $2K. The stake represents ﹤0.01% of the portfolio and ranks #306 among its holdings.

226 funds tracked by Wall St. Rank hold CORT as of Q4 2020.

Financial Gravity Asset Management held 86 shares of Corcept Therapeutics worth $2K as of Q4 2020.
Corcept Therapeutics was a new Financial Gravity Asset Management position in Q4 2020.
Corcept Therapeutics made up ﹤0.01% of Financial Gravity Asset Management's portfolio in Q4 2020, its #306 holding.
226 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2020.

Based on Financial Gravity Asset Management's 13F filing for Q4 2020, filed 16 Feb 2021.